Asthma Dx firm Aerocrine acquired by Circassia
This article was originally published in Clinica
Executive Summary
UK pharma firm Circassia Pharmaceuticals has agreed to buy Swedish asthma diagnostic specialist Aerocrine for SEK1.78bn ($219m). The offer of SEK2.55 per share is an 85% premium over Aerocrine’s share price on 22 April, when speculation of the acquisition first started.